Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Basic science, rationale, background and future of abatacept

Highly Accessed Review

Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?

Vivianne Malmström*, Christina Trollmo and Lars Klareskog

Author Affiliations

Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

For all author emails, please log on.

Arthritis Research & Therapy 2005, 7(Suppl 2):S15-S20  doi:10.1186/ar1505

Published: 16 March 2005

Abstract

Rheumatoid arthritis (RA) is a common destructive inflammatory disease that affects 0.5–1% of the population in many countries. Even though several new treatments have been introduced for patients with RA, a considerable proportion of patients do not benefit from these, and the need for alternative treatment strategies is clear. This review explores the potential for a therapy targeting the adaptive immune system by modulating co-stimulation of T cells with a CTLA4–Ig fusion protein (abatacept).